Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

adult ADHD

This page shows the latest adult ADHD news and features for those working in and with pharma, biotech and healthcare.

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug. Mydayis will reach the US market in the third quarter of the year. ... Being able to take a single dose is important, according to Shire because it is thought that more than half (56%) of adult

Latest news

  • Shire pitching at adult ADHD product launch in 2017 Shire pitching at adult ADHD product launch in 2017

    Shire pitching at adult ADHD product launch in 2017. Will have to first trial formulation in children to appease FDA. ... Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have

  • Lilly’s Strattera wins new adult ADHD licence in UK Lilly’s Strattera wins new adult ADHD licence in UK

    Lilly’ s Strattera wins new adult ADHD licence in UK. On course for wider EU approval for adults yet to receive treatment. ... King's College London and president of the UK Adult ADHD Network (UKAAN), “ and because primary and secondary care mental

  • Therapy focus: ADHD

    In fact, ADHD affects about 2 per cent of the world's adult population and as many as 65 per cent of children with ADHD may still have symptoms as adults. ... Around two-thirds of young offenders and up to half of the adult prison population have ADHD.

  • Targacept ADHD drug fails phase II study

    Targacept ADHD drug fails phase II study. An investigational treatment for adults with attention deficit/hyperactivity disorder that is being developed between AstraZeneca and Targacept has failed to meet the primary ... Top-line results of the study

  • Shire boosted by Vyvanse

    Shire boosted by Vyvanse. UK firm outperforms expectations on strong sales of new ADHD drug. ... We are anticipating the benefits of the back to school season for Vyvanse and are looking forward to increased sales momentum from our co-promote agreement

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    We are providing support to have a greater understanding of adult ADHD newly-diagnosed patients anwd get information on many domains of their life to better understand how the condition is ... At European level there is the adult ADHD indication - we are

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • ADHD perspectives series

    The ADHD in practice editorial board looks to represent this multi-disciplinary team providing insight and opinion. ... ADHD community can work together to provide the personalised 'scaffolding' from their perspective.

  • ADHD perspectives series

    The ADHD in practice editorial board looks to represent this multi-disciplinary team providing insight and opinion. ... ADHD community can work together to provide the personalised 'scaffolding' from their perspective.

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Congress Effectiveness Management
Maximising the ROI of scientific meetings...
Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...

Quick links

Infographics

Multimedia